No CrossRef data available.
Published online by Cambridge University Press: 17 May 2016
On May 11, 1993, the National Academy of Sciences hosted a workshop convened to address the scientific, medical, and social issues arising from attempts to enlist gene therapy experimentation in the fight against AIDS. The 100 participants represented a cross-section of federal governmental, industrial, academic, and research-practitioner expertise. I was invited presumably because I am a member of the Recombinant DNA Advisory Committee (RAC), an arm of the National Institutes of Health, which oversees (in effect, licenses) human gene therapy protocols, and because I have recently published reports bearing on that policy process (Carmen, 1992, 1993).